177734-79-1

Basic information

• Product Name: benzofuran-4-yl trifluoromethanesulfonate
• Synonyms: benzofuran-4-yl trifluoromethanesulfonate;4-(Trifluoromethylsulfonyloxy)benzofuran;Trifluoromethanesulfonic acid benzofuran-4-yl ester;1-benzofuran-4-yl trifluoroMethanesulfonate
• CAS NO: 177734-79-1
• Molecular Formula: C₉H₅F₃O₄S
• Molecular Weight: 266
• Mol File: 177734-79-1.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• Density: 1.586
• CAS DataBase Reference: benzofuran-4-yl trifluoromethanesulfonate(CAS DataBase Reference)
• NIST Chemistry Reference: benzofuran-4-yl trifluoromethanesulfonate(177734-79-1)
• EPA Substance Registry System: benzofuran-4-yl trifluoromethanesulfonate(177734-79-1)

Safety Data

• Hazardous Substances Data: 177734-79-1(Hazardous Substances Data)

Usage

General Description

Benzofuran-4-yl trifluoromethanesulfonate is a chemical compound that belongs to the class of organic compounds known as benzofurans. It is a synthetic reagent used in organic chemistry for various reactions, including the formation of carbon-carbon, carbon-nitrogen, and carbon-oxygen bonds. The trifluoromethanesulfonate group attached to the benzofuran ring makes it a good leaving group, allowing for efficient substitution reactions. benzofuran-4-yl trifluoromethanesulfonate is commonly used in the synthesis of pharmaceuticals, agrochemicals, and materials science, making it a valuable tool for the preparation of diverse chemical compounds in the laboratory.

Upstream product

• 480-97-7 4-hydroxybenzofuran 
• 407-25-0 trifluoroacetic anhydride 
• 112678-09-8 3-carboxy-4-hydroxybenzo-(b)-furan 
• 358-23-6 trifluoromethylsulfonic anhydride 

Downstream Products

• 95333-15-6 4-acetylbenzofuran 
• 166599-84-4 benzofuran-4-carboxylic acid 

Relevant articles and documents

Structure-activity relationships for analogs of the tuberculosis drug bedaquiline with the naphthalene unit replaced by bicyclic heterocycles

Replacing the naphthalene C-unit of the anti-tuberculosis drug bedaquiline with a range of bicyclic heterocycles of widely differing lipophilicity gave analogs with a 4.5-fold range in clogP values. The biological results for these compounds indicate on average a lower clogP limit of about 5.0 in this series for retention of potent inhibitory activity (MIC90s) against M.tb in culture. Some of the compounds also showed a significant reduction in inhibition of hERG channel potassium current compared with bedaquiline, but there was no common structural feature that distinguished these.

NOVEL TRICYCLIC CALCIUM SENSING RECEPTOR ANTAGONISTS FOR THE TREATMENT OF OSTEOPOROSIS

Novel tricyclic compounds of the formula (I): and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing osteoporosis and similar conditions. The compounds are effective as calcium sensing receptor antagonists. Pharmaceutical compositions and methods of treatment are also included.